Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

765 ARTÍCULOS , VIENDO DEL 316 AL 330

Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial

Ayasse ND, Stewart WF, Lipton RB, Gomez-Ulloa D, Runken MC.

Curr Alzheimer Res. 2024;21(5):353-365. doi: 10.2174/0115672050316936240905064215.

Progress of researches on the mechanism of acupuncture treatment for Alzheimer's disease by modulating synaptic plasticity

Ren DL, Wei YT, Su ML, Zhu TT, Yan XK.

Zhen Ci Yan Jiu. 2024 Aug 25;49(8):858-866. doi: 10.13702/j.1000-0607.20230279.

Phyto-nanotechnology: A novel beneficial strategy for Alzheimer's disease therapy

Ganguly SC, Sangram S, Paul S, Kundu M.

Neurochem Int. 2024 Nov;180:105868. doi: 10.1016/j.neuint.2024.105868. Epub 2024 Sep 25.

Non-Pharmacological Exercise Randomized Controlled Trials in Alzheimer's Disease

Wang N, Tai HC, Tzeng IS.

J Alzheimers Dis. 2024;101(s1):S537-S544. doi: 10.3233/JAD-240418.

The role and mechanism of dapagliflozin in Alzheimer disease: A review

Chen P, Liang L, Dai Y, Hui S.

Medicine (Baltimore). 2024 Sep 27;103(39):e39687. doi: 10.1097/MD.0000000000039687.

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

Jin M, Noble JM.

eNeuro. 2024 Sep 27;11(9):ENEURO.0088-24.2024. doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.

p38α Mitogen-Activated Protein Kinase-An Emerging Drug Target for the Treatment of Alzheimer's Disease

Detka J, Płachtij N, Strzelec M, Manik A, Sałat K.

Molecules. 2024 Sep 13;29(18):4354. doi: 10.3390/molecules29184354.

Therapeutic Efficacy of Extracellular Vesicles Derived from Stem Cell for Alzheimer's Disease: A Meta-Analysis Study

Deng H, Zhao J, Li J, Chen C, Hu Z, Wu X, Ge L.

Front Biosci (Landmark Ed). 2024 Sep 25;29(9):340. doi: 10.31083/j.fbl2909340.

Naringin and Naringenin: Potential Multi-Target Agents for Alzheimer's Disease

Lu J, Chen J, Li SY, Pan GJ, Ou Y, Yuan LF, Jiang JP, Zeng LH, Zhao J.

Curr Med Sci. 2024 Oct;44(5):867-882. doi: 10.1007/s11596-024-2921-z. Epub 2024 Sep 30.

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators

Jessen F, Kramberger MG, Angioni D, Aarsland D, Balasa M, Bennys K, Boada M, Boban M, Chincarini A, Exalto L, Felbecker A, Fliessbach K, Frisoni GB, Garza-Martínez AJ, Grimmer T, Hanseeuw B, Hort J, Ivanoiu A, Klöppel S, Krajcovicova L, McGuinness B, Mecocci P, de Mendonca A, Nous A, Ousset PJ, Paquet C, Perneczky R, Peters O, Tabuas-Pereira M, Piazza F, Plantone D, Riverol M, Ruiz A, Sacco G, Santana I, Scarmeas N, Solje E, Stefanova E, Sutovsky S, van der Flier W, Welsh T, Wimo A, Winblad B, Frölich L, Engelborghs S.

J Prev Alzheimers Dis. 2024;11(5):1212-1218. doi: 10.14283/jpad.2024.153.

Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies

Ramakrishnan V, Bender B, Langenhorst J, Magnusson MO, Dolton M, Shim J, Fuji RN, Monteiro C, Teng E, Kassir N, Jin J.

J Prev Alzheimers Dis. 2024;11(5):1241-1250. doi: 10.14283/jpad.2024.146.

A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD)

Gehlot P, Pathak R, Kumar S, Choudhary NK, Vyas VK.

Bioorg Med Chem. 2024 Nov 1;113:117925. doi: 10.1016/j.bmc.2024.117925. Epub 2024 Sep 14.

Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial

Koychev I, Reid G, Nguyen M, Mentz RJ, Joyce D, Shah SH, Holman RR.

Alzheimers Res Ther. 2024 Oct 2;16(1):212. doi: 10.1186/s13195-024-01573-x.

Gut microbiota and Alzheimer's disease: Exploring natural product intervention and the Gut-Brain axis for therapeutic strategies

Pasupalak JK, Rajput P, Gupta GL.

Eur J Pharmacol. 2024 Dec 5;984:177022. doi: 10.1016/j.ejphar.2024.177022. Epub 2024 Oct 1.

Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer's Disease and Associated Sleep Disorders

Carpi M, Mercuri NB, Liguori C.

Drugs. 2024 Nov;84(11):1365-1378. doi: 10.1007/s40265-024-02096-3. Epub 2024 Oct 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias